

Committee to Evaluate Drugs (CED)

Recommendations and Reasons

Document Posted: May 2015

Clindamycin / Benzoyl Peroxide gel

Product: clindamycin 1%/ benzoyl peroxide 3% gel (Clindoxyl® ADV Gel)

Class of Drugs: topical acne therapy

Reason for Use: moderate acne vulgaris

Manufacturer: GlaxoSmithKline Inc.

Date of Review: February 5, 2014

CED Recommendation

The CED recommended that clindamycin 1%/ benzoyl peroxide 3% gel (Clindoxyl® ADV Gel) not be funded. Similar products are already funded as benefits on the Ontario Drug Benefit Program and there is no evidence that Clindoxyl® ADV Gel provides added clinical benefit or cost-savings to the program.

Executive Officer Decision*

Based on the CED's recommendation, the Executive Officer decided not to fund clindamycin 1%/benzoyl peroxide 3% gel (Clindoxyl® ADV Gel).

Funding Status*

Not funded by the Ontario Public Drug Programs.

* This information is current as of the posting date of the document. For the most up-to-date information on Executive Officer decision and funding status, see: www.health.gov.on.ca/en/pro/programs/drugs/status_single_source_subm.aspx.

Highlights of Recommendation:

- Clindoxyl® ADV Gel (clindamycin 1%/benzoyl peroxide 3%) is a new formulation of Clindoxyl® Gel (clindamycin 1%/benzoyl peroxide 5%), which is listed as a General Benefit on the Ontario Drug Benefit Formulary.
- The Committee reviewed a randomized controlled trial that showed Clindoxyl® ADV Gel was more effective than clindamycin alone or benzoyl peroxide alone at reducing the number of acne lesions and severity.
- There are no clinical studies directly comparing Clindoxyl® ADV Gel to Clindoxyl® Gel or to other available clindamycin/benzoyl peroxide combination treatments. The relative effectiveness among these products is unknown.
- Side effects reported with Clindoxyl® ADV Gel include dermatitis and photosensitivity.
- Clindoxyl® ADV Gel costs \$41.14 for a 45 gram tube. The CED noted that although Clindoxyl® ADV Gel is the same price as Clindoxyl® Gel, less costly generic products may be available in the future.
- Overall, the CED noted that Clindoxyl® ADV Gel is a new formulation of topical clindamycin/benzoyl peroxide. Similar products are already available on the Ontario Drug Benefit Formulary, and there is no evidence that Clindoxyl® ADV Gel provides added clinical benefit or cost-savings to the program.

Background:

Acne is a dermatological disorder that results from the action of hormones and other substances on the skin's oil glands and hair follicles. Acne causes the skin's pores to become plugged and to break out into lesions commonly called pimples. Acne lesions usually occur on the face, neck, back, chest, and shoulders.

Acne treatments are selected based on the type and severity of acne. Drug treatments include topical and oral medications.

Clindoxyl® ADV Gel is a topical combination treatment containing clindamycin (an antibiotic) and benzoyl peroxide.

Detailed Discussions:

No additional relevant details.

Committee to Evaluate Drugs (CED)

The Committee to Evaluate Drugs (CED) is comprised of practicing physicians, pharmacists, health economists, and patient representatives. In conducting its review, the CED considers data contained in the drug manufacturer's submission, input provided by patient groups, findings from the national Common Drug Review and the pan-Canadian Oncology Drug Review, and other scientific information as necessary.

For more information, please contact:

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Hepburn Block, 9th Floor

80 Grosvenor Street, Queen's Park

Toronto, Ontario M7A 1R3

www.health.gov.on.ca/en/pro/programs/drugs/